MoonLake Immunotherapeutics (MLTX)
Automate Your Wheel Strategy on MLTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MLTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MLTX
- Rev/Share 0.0
- Book/Share 4.5951
- PB 3.3713
- Debt/Equity 0.2621
- CurrentRatio 8.5018
- ROIC -0.6237
- MktCap 1088924538.0
- FreeCF/Share -2.9335
- PFCF -5.8577
- PE -4.6271
- Debt/Assets 0.1828
- DivYield 0
- ROE -0.5625
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MLTX | Goldman | Neutral | Sell | -- | $10 | Jan. 15, 2026 |
| Upgrade | MLTX | BTIG Research | Neutral | Buy | -- | $24 | Jan. 9, 2026 |
| Upgrade | MLTX | H.C. Wainwright | Neutral | Buy | -- | $30 | Nov. 3, 2025 |
| Downgrade | MLTX | H.C. Wainwright | Buy | Neutral | -- | -- | Oct. 2, 2025 |
| Downgrade | MLTX | Goldman | Buy | Neutral | -- | $7 | Oct. 1, 2025 |
| Downgrade | MLTX | Wolfe Research | Outperform | Underperform | -- | $2 | Sept. 30, 2025 |
| Downgrade | MLTX | Citigroup | Buy | Neutral | -- | $5 | Sept. 30, 2025 |
| Downgrade | MLTX | Jefferies | Buy | Hold | -- | $8 | Sept. 29, 2025 |
| Downgrade | MLTX | BTIG Research | Buy | Neutral | -- | -- | Sept. 29, 2025 |
| Downgrade | MLTX | RBC Capital Mkts | Outperform | Sector Perform | -- | $10 | Sept. 29, 2025 |
News
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Published: November 10, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky
Published: November 10, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 10, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=176446&wire=5&utm_campaign=22 or contact Joseph E. Levi, Esq.
Read More
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or “SLK”), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or “HS”).
Read More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 15, 2025.
Read More
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) and certain of its officers.
Read More
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 04, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Nov. 4, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
ROSEN, NATIONAL TRIAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline.
Read More
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In MoonLake To Contact Him Directly To Discuss Their Options
Read More
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
Read More
MLTX SHAREHOLDER ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or “SLK”), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or “HS”).
Read More
MLTX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MoonLake To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake" or …
Read More
MLTX CLASS ACTION NOTICE: Berger Montague Encourages MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Nov. 3, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 15, 2025.
Read More
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate – Hagens Berman
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MoonLake Immunotherapeutics, Inc., (“MoonLake” or the "Company") (NASDAQ: MLTX) investors off a class action on behalf of investors that bought securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTX
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“Moonlake” or the “Company”) (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al.
Read More
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights – MLTX
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
Read More
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline.
Read More
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
Published: October 28, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders To Inquire About Securities Fraud Class Action.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the …
Read More
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
Published: October 27, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion. IF YOU SUFFER.
Read More
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline
Published: October 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)? Did you purchase your shares between March 10, 2024 and September 29, 2025, inclusive?
Read More
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
Published: October 24, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Oct. 24, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al.
Read More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Published: October 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 15, 2025.
Read More
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX).
Read More
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors
Published: October 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MoonLake Immunotherapeutics, Inc., (“MoonLake” or the "Company") (NASDAQ: MLTX) investors off a class action on behalf of investors that bought securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX
Published: October 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025.
Read More
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) and certain of its officers.
Read More
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Oct. 21, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al.
Read More
About MoonLake Immunotherapeutics (MLTX)
- IPO Date 2020-10-20
- Website https://www.moonlaketx.com
- Industry Biotechnology
- CEO Jorge Santos da Silva
- Employees 100